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Management of Norovirus and Clostridium diﬃcile gastroenteritis is challenging for rehabilitation and long-
term care facilities. We evaluated the contribution of a 2-step laboratory-based strategy, including a new
ready-to-use Norovirus polymerase chain reaction assay to promote isolation precautions. C diﬃcile and
Norovirus were successively identiﬁed from 17% and 23% of 52 episodes of diarrhea, respectively, during
the winter season, leading to 100% adequate isolation measures. In patient populations with numerous
risk factors for diarrhea, a combined laboratory-based approach could improve infection control.
© 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Gastroenteritis is a major cause of hospital-acquired infec-
tions, involving primarily Clostridium diﬃcile (Cd) or Norovirus (Nv).1,2
These agents require prompt and speciﬁc infection control mea-
sures to prevent secondary cases among patients and, for Nv, health
care professionals and visitors.1,3 In rehabilitation care facilities (RCFs)
and long-term care facilities (LTCFs) outbreaks are diﬃcult tomanage
because of the dependency of patients, low health care profession-
al to patient ratio, and single room scarcity.3-6 Product and process
innovations are essential to improve Nv and Cd detection. In the
present pilot study we prospectively evaluate the contribution of
a new 2-step, laboratory-triggered strategy based on the succes-
sive polymerase chain reaction (PCR) detection of Cd and Nv.
MATERIALS AND METHODS
Population sampling and study period
The Emile Roux facility has 397 RCF beds and 387 LTCF beds, with
half of the rooms being single-bed rooms. The study period was
February-April 2015.
Microbiologic testing
We compared 2 different approaches during the study
period. The ﬁrst approach was a standard approach that was his-
torically implemented and included Nv or Cd testing only at the
request of clinicians or infection control practitioners using an
immunochromatographic test (ICT) (RidaQuick Norovirus;
R-Biopharm, Darmstadt, Germany) or a PCR assay (Xpert C. diﬃcile;
Cepheid, Sunnyvale, CA) within a 1-hour turnaround time (TAT).
The second approach was a new 2-step laboratory-based ap-
proach using PCR assays: Nv were tested on the initiative of the
laboratory on each Cd negative stool specimen using a new PCR assay
according to the manufacturer’s recommendations. This new mo-
lecular assay (Xpert Norovirus; Cepheid) detects the 2 main human
genogroups (GI and GII) over 90 minutes.
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These 2 approaches were tested simultaneously during the same
period to limit confounding factors. The result of each test was im-
mediately transmitted to the infection control team to verify the
implementation of precautions measures. Only 1 episode per patient
was included. Patients were informed, and consent was obtained.
Data collection
The following data were collected from patient ﬁles: history
of antibiotic, acid-suppressive, or laxative consumption;
Cd infection; active chronic bowel inﬂammatory disease;
immunosuppression (including active malignancy or transplanta-
tion); chronic renal failure; mobility; cognitive impairment; and
dependency. Regarding the present diarrheic episode, the date of
the ﬁrst clinical sign, stool specimen collection, and contact pre-
caution implementation were collected.
RESULTS
During the study 52 episodes of diarrhea were analyzed. Pa-
tients’ characteristics were reported in Table 1: most patients were
older adults, dependent, mobile, and disoriented. Positive Cd PCR
was obtained for 9 of the 52 patients (17%). The Nv PCR per-
formed for all of the Cd-negative specimens was positive in 10 of
43 (23%) patients (all GII). Considering the former standard ap-
proach, only 19 out of 43 Cd-negative specimens were tested for
Nv, yielding 3 positive ICT (GII) and 1 uninformative result. In ad-
dition to the 3 ICT-positive patients, the study protocol allowed the
identiﬁcation of 7 additional Nv-positive cases. No false-negative
ICT result was detected. Therefore, the improved performance of
the new approach was caused by the laboratory-triggered Nv testing
on Cd-negative specimens rather than the PCR detection of ICT false-
negative specimens: only the uninformative ICT result tested positive
using the new Nv PCR assay, whereas no ICT-negative specimen
tested positive using this PCR-based approach. Considering the new
PCR combined strategy, an infectious agent was identiﬁed in 19 of
the 52 (37%) patients.
At the time of specimen collection, 5 of the 52 patients were
under contact precautions, with 2 patients being PCR positive for
Cd and 1 patient being PCR positive for Nv. Once the PCR results
were transmitted, all of the Cd- or Nv-positive patients were placed
under contact precautions.
DISCUSSION
Cd and Nv are the 2 main agents responsible for extensive gas-
troenteritis outbreaks in RCFs and LTCFs.3-6 As expected, our study
population accumulated risk factors for Cd infection.5 Laxative medi-
cations promote Cd infections and mime infectious diarrhea. This
confounding condition (36/52 patients) could explain the delete-
rious delay between the onset of symptoms and stool testing. In our
study, physicians widely prescribed speciﬁc Cd testing but not pre-
emptive contact isolation thatmeets with its psychosocial deleterious
consequence and the decreasing compliance rate with increasing
burden of isolation.1,7 Rapid diagnostic tests are recommended to
support clinical decision, but stool testing practices vary across
facilities.8 In the present instance the availability of a rapid and sen-
sitive nucleic acid ampliﬁcation test could limit the risk of
cross-transmission.
Early detection of sporadic NV cases during the seasonal period
cost-effectively prevents outbreaks.2,3 The diagnosis of Nv would
beneﬁt from easy-to-use and more sensitive methods.2 Neither
ICT with a poor sensitivity (17%-92%) nor conventional PCR with
inadequate availability and TAT encouraged clinicians to prescribe
speciﬁc Nv testing.2 A recent report from English hospitals under-
lined the weak percentage of stools testing with a targeted pathogen
demand (20.2%) and the better infection control practices when
the infectious status of diarrhea was conﬁrmed.8 These data
supported the implementation of a laboratory-based nucleic acid
ampliﬁcation test strategy. Our PCR assays are based on a user-
friendly platform allowing a random-access PCR-based diagnosis
of numerous infectious agents without technical skills require-
ment. Because of its analytical performance, this PCR assay could
facilitate Nv diagnosis.9 To our knowledge, our work reports for
the ﬁrst time the implementation of this test in a prospective
clinical study, focusing on its putative contribution in infection
control. Within a maximum TAT of 3 hours, our approach could
accurately identify the 2 main infectious agents responsible for
gastroenteritis outbreaks. Our work cannot be reduced to a simple
Table 1
Characteristics of the patients suffering from diarrhea, including results from Cd and Nv PCR testing
Characteristic Total (N = 52)
Cd positive
(n = 9)
Cd negative, Nv
positive (n = 10)
Mean age (range), y 87 (75-103) 88 (84-92) 90 (82-103)
Sex ratio, M/F 0.31 0.44 0.11
History of antibiotic consumption in the previous month 39 (75.0) 9 6
History of acid-suppressive consumption in the previous month 27 (51.9) 7 2
History of laxative consumption
In the previous month 36 (69.2) 8 7
In the previous week 33 (63.5) 8 4
History of Cd infection in the previous year 4 (7.7) 2 0
Chronic bowel inﬂammatory disease 3 (5.7) 0 0
Chronic renal insuﬃciency 10 (19.2) 0 2
Immunosuppression 5 (9.6) 3 1
Dependency 35 (67.3) 7 6
Cognitive impairment 32 (61.5) 5 5
Mobility 42 (80.8) 6 9
At the time of the episode of diarrhea, presence of
Fever (>38.5°C) 4 (7.7) 1 2
Vomiting or nausea 23 (44.2) 5 8
Average delay between the onset of the symptoms and the specimen collection (range), d 3.3 (0-32) 3.1 (0-32) 3.6 (0-19)
Average delay between admission and specimen collection (range), d 201 (0-3,925) 163 (0-732) 16 (0-5)
NOTE. Values are listed as n (%), n, or as otherwise indicated.
Cd, Clostridium diﬃcile; F, female; M, male; Nv, Norovirus; PCR, polymerase chain reaction.
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comparison between the ICT and PCR detection of Nv: this issue
has been widely addressed in the literature and supported the
implementation of a PCR-based assay.2 However, in our study we
did not identify any false-negative ICT result: this could be ex-
plained by the low number of ICT-tested specimens or the
performance of the marketed ICT assay that ranked ﬁrst in a
recent comparative study.10 We focused on the putative pivotal
role of the laboratory that could be the mainspring of the testing
strategy to detect the 2 main agents responsible for gastroenteri-
tis among patients from RCFs and LTCFs. Our 2-step laboratory-
based strategy seems to be economical and eﬃcient: the 37%
positive rate was similar to the 37.8% of tests identifying a single
infectious agent in a recent large European study.11 In the near
future this strategy will be challenged by syndromic PCR panels,
including bacteria, virus, and parasites, that could be of great
interest for infection control purposes.11,12 Nevertheless their cost
and the debating infection control relevance of some of the
targeted microorganisms could limit their implementation. Our
pilot study has several limitations: we could not prove that our
strategy prevents outbreaks of Nv: the study lacks a control arm
and does not count secondary cases. Our approach missed Nv and
Cd coinfections that were recently reported in LTCFs.13 However,
the contact precautions that were recommended for Cd infection
could prevent Nv contamination, except for viral airborne
transmission.2 Additionally, we performed our study during the
seasonal peak of Nv, among a mobile population presenting
numerous confounding and risk factors for infectious and nonin-
fectious diarrhea, in a context of limited availability of single
rooms and low preemptive isolation measures. These conditions
could have maximized the contribution of our proactive laboratory-
based strategy.
To conclude, this study underlines the signiﬁcant contribution
of a laboratory-based strategy, including a new ready-to-use Nv PCR
assay, to adequately implement isolation precautions for diarrheic
patients from RCFs and LTCFs.
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